ENZC (Enzolytics) Short-Term Debt: $0.12 Mil (As of Jun. 2011)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Enzolytics Short-Term Debt?

Enzolytics ENZC Short-Term Debt is $0.12 Mil as of Jun. 2011.

Enzolytics's Short-Term Debt for the quarter that ended in Jun. 2011 was $0.12 Mil.

Enzolytics's quarterly Short-Term Debt increased from Dec. 2010 ($0.24 Mil) to Mar. 2011 ($0.28 Mil) but then declined from Mar. 2011 ($0.28 Mil) to Jun. 2011 ($0.12 Mil).

Enzolytics's annual Short-Term Debt increased from Jul. 2008 ($0.00 Mil) to Dec. 2009 ($0.29 Mil) but then declined from Dec. 2009 ($0.29 Mil) to Dec. 2010 ($0.24 Mil).

Enzolytics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Enzolytics Short-Term Debt Related Terms

Enzolytics Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Enzolytics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enzolytics Short-Term Debt Chart

Enzolytics Annual Data
Trend Dec07 Jul08 Dec09 Dec10
Short-Term Debt
0.07 0.00 0.29 0.24

Enzolytics Quarterly Data
Sep07 Dec07 Apr08 Jul08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.69 0.65 0.24 0.28 0.12
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.12 Mil mean?
Enzolytics (ENZC) has a Short-Term Debt of $0.12 Mil as of Jun. 2011.
Is Enzolytics' Short-Term Debt too high?
Enzolytics' current Short-Term Debt is $0.12 Mil.
How does Enzolytics' Short-Term Debt compare to competitors?
Enzolytics' Short-Term Debt of $0.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Enzolytics's current Short-Term Debt is $0.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzolytics stock overvalued right now?
Enzolytics (ENZC) has a current Short-Term Debt of $0.12 Mil. The current Short-Term Debt is $0.12 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Enzolytics (ENZC), the current Short-Term Debt is $0.12 Mil as of Jun. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Enzolytics Business Description

Address 1101 Raintree Circle, Suite 130, Allen, TX, USA, 75013
Enzolytics Inc is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. The company is committed to creating drugs for the good health of mankind. ENZC's flagship compound, ITV-1, is a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system. IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use.